30,980 Alzheimer's and dementia studies in plain English, each scored out of 100.
The study of patients with semantic dementia, a variant of frontotemporal lobar degeneration, has emerged over the last two decades as an important lesion model for studying human semantic memory. 4 key findings →
Participants: 21 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The weighted prevalence of dementia based on the 10/66 Diagnostic Research Group (DRG) criteria was 8.8% (95% confidence interval [CI]: 7.3-10.7) in the WiSE 2023 study compared to 10% in the WiSE 2013 study (95% CI: 8.7-11.5). 5 key findings →
Design: cross-sectional Participants: 2,010 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Evidence links air pollution to dementia, yet its role in Lewy body dementia (LBD) remains unclear. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Bariatric surgery was associated with a significantly reduced incidence of ADRD, evidenced by a subdistribution hazard ratio (SHR) of 0.37 (95% confidence interval [CI]: 0.15–0.89; P = 0.03). 4 key findings →
Design: longitudinal study Participants: 5,303 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Meta-analysis identified 44 CpGs and 44 differentially methylated regions consistently associated with time to dementia in both cohorts. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Data from 1,272,495 individuals, with the mean age at diagnosis ranging from 76.8 years (South Korea) to 82.9 years (Germany), show that the overall median length of survival following recorded diagnosis ranges from 2.4 years (New Zealand) to 7.9 years (South Korea). 2 key findings →
Design: cohort study Participants: 1,272,495 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among our participants, aMCI and VCIND demonstrated prevalence of 14.83% and 2.71%, respectively, and annual incidence (per 1000 person-years) of 69.6 and 10.6, respectively. 5 key findings →
Design: longitudinal study Participants: 2,051 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
in 1997, the prevalence of Alzheimer's disease in the United States was 2.32 million (range: 1.09 to 4.58 million); of these individuals, 68% were female. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
A simple analysis of funnel plots provides a useful test for the likely presence of bias in meta-analyses, but as the capacity to detect bias will be limited when meta-analyses are based on a limited number of small trials the results from such analyses should be treated with considerable caution.
Full summary, score breakdown and related studies → Original source Free full text
Trisomy 21, the presence of a supernumerary chromosome 21, results in a collection of clinical features commonly known as Down syndrome (DS). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The relationship between depression and dementia is complex and still not well understood. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Plasma p-tau217 and p-tau231 were most effective in diagnosing aMCI/AD (AUC = 0.95 and 0.93, respectively), while p-tau217, p-tau231 and p-tau181 presented the best differential diagnosis for AD from PSP, FTD and DLB respectively (AUC = 0.84, 0.81 and 0.83). α-synuclein was presented as the best biomarker for PSP variant and behavior variant FTD subtypes (AUC = 0.81 and 0.74, respectively). 5 key findings →
Design: cross-sectional Participants: 668 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We found no significant difference in dementia incidence over a 20‐year follow‐up period compared with matched TIA‐free controls. 3 key findings →
Design: cohort study Participants: 297 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Compared with those without CMD, those with CMD multimorbidity had an elevated risk of ACD (hazard ratio [HR]: 2.27, 95% confidence interval [95% CI]: 1.95-2.63), AD (HR: 1.49, 95% CI: 1.13-1.97), and VD (HR: 3.70, 95% CI: 2.93-4.69). 5 key findings →
Design: cohort study Participants: 287,748 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of 510 memory-clinic subjects(N = 155 cognitive decline), RetiPhenoAge associated with incident cognitive decline (subdistribution hazard ratio [SHR] 1.34, 95% confidence interval [CI] 1.10-1.64, p = 0.004), and incident dementia (SHR 1.43, 95% CI 1.02-2.01, p = 0.036). 5 key findings →
Participants: 155 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We identified 62 928 patients with OSA and 62 928 in the propensity score-matched comparison cohort (76% male, median age 52 years). 5 key findings →
Design: cohort study Participants: 928 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Each 1-unit increase in cumulative score was associated with a 3%-8% higher dementia hazard across cohorts. 5 key findings →
Design: cohort study Participants: 23,305 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Individuals with both physical frailty and depression had the highest risk of dementia. 5 key findings →
Design: longitudinal study Participants: 947 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The GBT model achieved the best AUC-ROC scores of 0.809-0.833 across 1- to 5-year prediction windows. 4 key findings →
Design: case-control study Participants: 380,269 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In our dataset search, we identified 108 910 people with a record indicating dementia at any time. 5 key findings →
Design: cohort study Participants: 9,819 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among the 393 497 All of Us participants with linked EHRs, we identified 9444 individuals (2.40%) with glaucoma diagnoses (excluding participants with diagnoses of dementia before glaucoma) and 37 776 matched controls without glaucoma. 5 key findings →
Design: cohort study Participants: 5,756 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The number of people with clinical AD will increase as the "baby boom" generation reaches older ages, exerting a strong upward influence on disease burden.
Full summary, score breakdown and related studies → Original source Free full text
In this cross-sectional study examining generational differences in age-specific dementia prevalence across the US, Europe, and England, we found that individuals from more recent birth cohorts had lower proportions of people with dementia. 4 key findings →
Design: cross-sectional Participants: 62,437 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In Fine-Gray models, dementia risk was higher in female than in male participants (subdistribution hazard ratio [sHR] 1·89, 95% CI 1·30-2·76) and Black than Asian participants (sHR 1·75, 1·07-2·88), lower in APOE ε2 carriers than in non-carriers (sHR 0·39, 0·17-0·88), and not significantly higher in APOE ε4 carriers than in non-carriers (sHR 1·51, 0·92-2·47). 3 key findings →
Design: cohort Participants: 805 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Although air pollution is well known to be harmful to the lung and airways, it can also damage most other organ systems of the body. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,980 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,980 records, built mostly from automated pulls of Europe PMC (65.2% of the library) and OpenAlex (16.4%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,042 records (3.4% of the library) are not peer-reviewed — 967 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events